Connect with us

Technology

Cure and The New York Academy of Sciences to Co-Host Forum on Science and Business of AI-Driven Drug Discovery

Published

on

AI and pharma thought leaders to share insights on transformative role of AI in drug discovery and development for personalized medicine, rare diseases and more

NEW YORK, June 24, 2024 /PRNewswire/ — Cure.®, a healthcare innovation campus in New York City, and The New York Academy of Sciences, an organization committed to advancing science and technology for the benefit of society, today announced an exciting two-part science technology seminar: Science and Business of AI-Driven Drug Discovery and Deepfakes & Democracy in the Age of AI.

Thought leaders in artificial intelligence and biopharmaceuticals will share their insights on how AI and machine learning accelerate target identification, predict compound interactions, and optimize clinical trial designs. Attendees will gain valuable perspectives on the potential for AI to drive personalized medicine and tackle rare diseases, among other potential applications.

Event Details for Science and Business of AI-Driven Drug Discovery

Date: Tuesday, June 25Time: 5:00 – 7:00 PM EDTVenue: Cure, 345 Park Avenue South, New York, NYRegistration: Science and Business of AI-Driven Drug Discovery Seminar

Speakers:

Maria Luisa Pineda, PhD, Co-Founder and CEO of EnvisagenicsGrant Mitchell, MD, MBA, Co-Founder and CEO of Every CureAndrea Califano, PhD, Chair, Department of Systems Biology, Columbia University and President, Chan Zuckerberg Biohub New York

Opening remarks will be made by Nicholas B. Dirks, PhD, President and CEO, The New York Academy of Sciences, and the seminar will be moderated by Seema Kumar, CEO of Cure.

“AI-driven drug discovery is poised to revolutionize the biopharmaceutical industry by enhancing drug development efficiency, accuracy, and cost-effectiveness,” said Nicholas B. Dirks, President and CEO of The New York Academy of Sciences. “These technological advancements promise to bring more effective treatments to patients faster, marking a significant milestone in modern medicine and public health.”

With only about 10 percent of drug candidates making it through a typical development time of 12 to 18 years, the ability of AI and ML tools to optimize discovery has become an area of intense interest. The influx of substantial financial commitments from private and public sectors drives new collaborations and innovations.

“Our goal is to showcase real world examples from biotech and life science leaders who are already using AI and ML tools to develop new products, transform clinical trials, and work with regulators,” said Cure CEO Seema Kumar. “They will share examples of how these tools are changing the trajectory of healthcare research today and transforming the landscape for a healthier tomorrow.”

Information for Deepfakes & Democracy in the Age of AI will be available soon.

About Cure.
Cure is a healthcare innovation campus in the heart of New York City that features laboratory and business facilities, a collaboration residency, office space and premium event venues, including an education center, conference center, and iconic rooftop facility, as well as tools, mentoring, networking, and other assistance to members of its ecosystem. Cure houses on-campus startups and established companies. Residents regularly create synergies and collaborative partnerships with peer organizations across the spectrum of healthcare, from academic or private to non-profit or government, and focus on diagnostic, device, drug or vaccine discovery, development and production as well as care delivery and public health. Cure also offers industry-leading event programming focused on critical health topics. Cure’s mission is to foster and accelerate advances in health. For more information, please visit wewillcure.com.

About The New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science for the benefit of society. With more than 20,000 Members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM-related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online at www.nyas.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cure-and-the-new-york-academy-of-sciences-to-co-host-forum-on-science-and-business-of-ai-driven-drug-discovery-302180739.html

SOURCE Cure

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

In Turfan, Xinjiang, China’s first commercially operated microgrid has generated nearly 100 million kWh of electricity

Published

on

By

TURFAN, China, Nov. 15, 2024 /PRNewswire/ — On November 13, the Turfan New Energy City Microgrid Demonstration Project, China’s first commercially operated microgrid demonstration project, generated nearly 100 million kWh of electricity, equivalent to saving 29,000 tons of standard coal and reducing carbon dioxide emissions by 77,600 tons.

A microgrid refers to a small-scale power generation and distribution system organized by distributed power sources, power loads, distribution facilities, monitoring and protection devices, etc., which can realize flexible control and autonomous management. Since the end of 2013, the project had been the largest and most comprehensive solar energy utilization and building integration project in China up to that time, with 8.7 MW of photovoltaic power installed on the roofs of 223 residential buildings, generating an annual power capacity of about 10 million kWh.

To promote the physical operation of the project, the State Grid Turfan Power Supply Company invested more than 2 million yuan to cooperate in the construction of microgrid infrastructure, fully supporting the online operation of surplus new energy power generation, promoting the comprehensive utilization of renewable resources in urban buildings, and helping Turfan build a high-quality development demonstration area and a green and low-carbon pilot area.

View original content:https://www.prnewswire.com/apac/news-releases/in-turfan-xinjiang-chinas-first-commercially-operated-microgrid-has-generated-nearly-100-million-kwh-of-electricity-302306810.html

SOURCE State Grid Turfan Power Supply Company

Continue Reading

Technology

Innovations in Guiyang: Adhering to New Industrialization and Promoting High-End, Intelligent and Green Manufacturing

Published

on

By

GUIYANG, China, Nov. 15, 2024 /PRNewswire/ — A report by Huanqiu.com

The wave of new industrialization in Guiyang is driving the transformation and upgrading of the manufacturing industry in ways like never before. Guiyang is always strategically oriented toward “industrial structure optimization with a focus on industries”, and has made all efforts to develop “four major industrial bases”, highlighting its industrial economy as the “primary driving force” behind development. Especially relying on its policy edge in renewable energy, Guiyang has rapidly emerged as a national new-energy power battery and materials research, development and production center, injecting strong momentum into the city’s economy.

In October 2023, the CATL (Guizhou) New Energy Power and Energy Storage Battery Production Base, located in Gui’an New Area, Guizhou Province, was put into production. The first phase of the base boasts cutting-edge design standards, characterized by “lighthouse + zero carbon factory”. The high-standard facility employs advanced, high-speed, highly automated, and flexible production lines. It is designed to have an annual production capacity of 30 GWh. After the base achieves the designed production capacity, its annual output value is expected to reach 15 billion yuan. According to statistics, the base realized an industrial output value of 618 million yuan in the first half of 2024, and the year’s industrial output value is expected at about 2 billion yuan.

The Chery (Guizhou) industrial base has also yielded unusually brilliant results in the field of new energy vehicles (NEVs), where Chery Automobile’s self-developed “CHEVOO” new-generation light truck KL71 project is undergoing four-pillar car road tests. The advanced pressing, welding, painting and assembly lines, as well as the R&D lab and the all-electric truck production line, together constitute this “digital intelligent” NEV factory. Moreover, the Chery (Guizhou) industrial base has built, extended and strengthened its vehicle manufacturing industry chain so as to master key parts supply chains and reduce development costs.

The Gui’an FinDreams battery project, as an important move of BYD in Guiyang, is also showing its strength in power batteries for NEVs. FinDreams Battery Co., Ltd. at Longshan Industrial Park in Gui’an New Area has four automatic production lines that are operating at high speeds in the workshop, which produce “blade batteries” which are well-known both in and out of the industry. According to reports, 300 battery packs and 40,000 cells can be produced per day.

Guiyang’s “four bases” – a new energy vehicles and battery materials production base, a resource deep-processing base, a computing power assurance base, and an industrial backup base, contribute greatly to the development of NEV and battery materials industry, electronic information manufacturing industry, and advanced equipment manufacturing industry, etc. Data show that in the first three quarters, the added value of Guiyang’s industrial enterprises above designated size grew by 11%, and the contribution of industrial economy to economic growth reached 39.4%.

Photo – https://mma.prnewswire.com/media/2558773/image.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/innovations-in-guiyang-adhering-to-new-industrialization-and-promoting-high-end-intelligent-and-green-manufacturing-302306825.html

Continue Reading

Technology

Premialab appointed by Lombard Odier Investment Managers to scale Quantitative Investment Strategies

Published

on

By

Premialab’s technology chosen to enhance QIS scaling, operational efficiency, and risk management.

PARIS, Nov. 15, 2024 /PRNewswire/ — Lombard Odier Investment Managers (LOIM), the institutional asset management business of the Lombard Odier Group, has integrated Premialab‘s industry-leading technology to support the management of their soon-to-be-launched DOM Global Macro strategy. This partnership underscores LOIM’s commitment to onboard innovative strategies in an evolving market landscape.

“Our decision to partner with Premialab is driven by their comprehensive risk management and regulatory compliance expertise,” said Didier Anthamatten, Portfolio Manager at LOIM. “With a strong track record in alternative investments, LOIM remains focused on delivering innovative investment solutions and high-quality returns for our clients. Premialab’s advanced data capabilities are essential in helping us maintain our rigorous standards and provide robust, risk-adjusted performance. Additionally, their platform perfectly matches the DOM Global Macro strategy’s needs, enhancing our risk monitoring capabilities and streamlining portfolio management.”

The DOM Global Macro strategy expects to leverage Premialab’s unique dataset. The full lookthrough across all DOM’s proprietary systematic strategies allows granular risk decomposition and scenario-based analysis at the entire portfolio level. This should help monitoring exposures’ attractiveness, from both time-series and cross-sectional perspectives, and optimizing asset allocation.

Neil Richards, Head of EMEA Business Development at Premialab, said the collaboration with LOIM is a significant addition to Premialab’s growing business in Switzerland and within the wider European markets.

“Institutions such as LOIM, which oversees a substantial portfolio across various asset classes, need continuous monitoring and adjustment to keep their investments on track,” he explained. “Premialab provides the tools for benchmarking and stress testing their systematic investments, ensuring that LOIM’s mandates are effectively managed in terms of cost, risk, and value.”

Premialab CEO Adrien Géliot highlighted that the QIS sector is experiencing rapid growth, driven by institutional investors seeking liquid, transparent, and cost-efficient investment strategies. “Premialab sits at the centre of the QIS landscape, uniquely positioned to aggregate and make sense of the vast and growing universe of data,” he stated. “We are thrilled to be partnering with LOIM to deliver our unique data and risk monitoring capabilities to one of the top global investment firms.”

Premialab’s multi-asset, multi-region platform handles 10 million data points daily. It analyzes over 5,000 investible systematic strategies, with client assets under management totalling approximately USD $20 trillion. Combining the Premialab platform with Premialab Pure Factors®, it provides comprehensive cross-asset quantitative strategy selection and thorough due diligence on strategies available worldwide. Additionally, the platform enhances risk management and reporting capabilities, including expedited and detailed regulatory reporting.

With its unique combination of systematic strategies and discretionary trading, the DOM Global Macro strategy clearly benefits from Premialab’s state-of-the art data analysis capabilities and computational efficiency. The Portfolio and Risk Managers can thus use a shared dataset for risk analysis and performance decomposition, enhancing the portfolio’s robustness and operational efficiency.

About Premialab
Premialab is the leading independent platform that collaborates with leading investment banks and institutional investors globally, providing data, analytics, and risk solutions for systematic, factor, and multi-asset strategies. With offices in London, Paris, New York, Hong Kong, Dubai and Sydney, the company has forged strong partnerships with the top 18 investment banks, asset managers, pension funds, sovereign wealth funds and insurance companies globally.

About Lombard Odier Investment Managers (LOIM)
Lombard Odier Investment Managers (LOIM) is the institutional asset management business of the Lombard Odier Group, wholly owned and funded by its partners since its establishment in 1796.

We provide a range of investment solutions to a diverse group of long-term oriented clients. Our heritage, and our combination of the best of conservatism and innovation, keeps us well positioned to create lasting value for our clients. Our investment capabilities span fixed income, convertible bonds, equities, multi-asset, and alternatives. Sustainability is central to our investment philosophy; we believe it is the founding principle of long-term economic and investment outcomes and will drive returns over the long term.

With over 200 investment professionals, we are a global business with a network of 13 offices across Europe, Asia and North America and have assets under management of CHF 64 billion (as at 31 September 2024).

View original content:https://www.prnewswire.com/de/pressemitteilungen/premialab-appointed-by-lombard-odier-investment-managers-to-scale-quantitative-investment-strategies-302306411.html

Continue Reading

Trending